久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

國藥集團 Sinopharm
中國醫藥集團是由國務院國資委直接管理的中國最大的醫藥健康產業集團，以預防治療和診斷護理等健康相關產品的分銷、零售、研發及生產為主業。中國醫藥集團成立于1998年，由中國醫藥（集團）公司、中國醫藥工業公司、中國醫藥對外貿易總公司、中國醫療器械工業公司4家企業聯合組建而成。2003年中國藥材集團進入集團、2009年集團與中國生物技術集團公司聯合重組、2010年上海醫藥工業研究院、中國出國人員服務總公司進入集團。目前集團旗下擁有十家全資或控股子公司，國藥控股一家H股上市公司及國藥股份、天壇生物、現代制藥、一致藥業四家A股上市公司。中國醫藥集團2011年實現營業收入超過1200億元。

中國醫藥集團正在全力推進集團五大平臺——現代物流分銷一體化平臺、產學研一體化科技創新平臺、國際經營一體化平臺、醫療健康產業平臺、高效管控與融合協同一體化平臺的全面建設，依托集團五大平臺協同運作，促進集團十一個核心業務——醫藥現代物流分銷、醫藥零售、生物制品、化學制藥、現代中藥、診斷試劑與化學試劑、科學儀器與醫療器械、醫藥科研與工程設計、醫藥國際經營與海外實業、醫藥會展與傳媒、醫療健康產業的全面發展，構成了一個完整的中央企業醫藥健康產業平臺，實現了規模效益，推動業績高速增長。2003年至2011年中國醫藥集團營業收入年平均增幅33%，利潤總額年平均增幅44%，總資產年平均增幅35%。目前已擁有覆蓋全國31個省、自區、直轄市的醫藥流通配送網絡和與國際水平接軌的30個配送中心及生產基地。中國醫藥集團在國內擁有一流的醫藥及疫苗、血液制品生產企業、高水平的科研設計院所、覆蓋全國的營銷絡、大規模的藥材種植基地及全國第一的醫藥會展，產業鏈完整。從1980年開始先后與國外的著名跨國醫藥公司合作，建立了中國大冢制藥有限公司、無錫華瑞制藥有限公司等20家中合資醫藥生產企業，與美國、日本、法國、英國、德國、意大利、韓國等多個國家開展了國際技術合作項目，并與世界上100多個國家和地區建立了貿易和合作關系，有力地促進了我國醫藥生產經營和醫藥行業管理水平的提高。

中國醫藥集團以“關愛生命、呵護健康”為企業理念，其所屬企業承擔著全國搶險救災藥品、生物技術產品、中藥材、醫療器械的中央儲備、調撥和供應任務，在1976年唐山大地震、1998年抗洪搶險、2003年抗擊非典的戰斗中；在2008年汶川抗震救災、2009年防控甲型H1N1流感疫情、2010年玉樹和舟曲抗震救災的現場；在2008年奧運會、2009年國慶閱兵和2010年上海世博會等重大事件醫藥物資儲備與應急供應，以及2010年國家麻疹疫苗強化免疫活動中，都能看到國藥人緊張工作的身影，為保障人民的生命健康和社會穩定發揮了重要作用。同時, 集團研發生產的疫苗出口到印度、泰國、韓國、尼泊爾、斯里蘭卡等國，為當地民眾健康做出了積極貢獻。

中國醫藥集團總公司是中國化學制藥工業協會、中國麻醉藥品協會、中國醫藥商業協會、中國醫藥科研開發促進會、中國醫療器械行業協會、中國中藥協會、中國藥文化研究會等行業組織的會長或理事長單位，還是全國藥品交易會等重要會展的主辦和支持單位。

中國醫藥集團的發展目標是，“十二五”期間，建成涵蓋醫藥行業全產業鏈的，具有行業帶動力和國際競爭力的大型醫藥健康產業集團，成為進入世界500強的第一家中國醫藥健康企業。

China National Pharmaceutical Group Corporation, (Sinopharm) is the largest medical and healthcare group in China which is directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the core businesses of distribution, logistics, retail, scientific research and manufacture of healthcare related products. Associated built on the basis of the four state-owned companies: China National Pharmaceutical (Group) Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Equipment Industry Corporation, Sinopharm was established in 1998. In 2003, China National Group Corporation of Traditional & Herbal Medicine joined Sinopharm. In 2009, Sinophrm restructured with China National Bio-tech Group (CNBG). As well as in 2010, Shanghai Institute of Pharmaceutical Industry (SIPI) and China National Service Corporation for Chinese Personnel Working Abroad (CNSC) joined Sinopharm. So far, Sinopharm owns 10 wholly owned or holding subsidiaries, and 5 listed companies including Sinopharm Group Co., Ltd. (01099.HK), China National Medicines Co., Ltd. (600511.SH), Beijing Tiantan Biological Products Co., Ltd. (600161.SH), Shyndec Pharmaceutical Co., Ltd. (600420.SH) and Shenzhen Accord Pharmaceutical Co., Ltd. (200028.SZ). The sales revenue of Sinopharm exceeded RMB 160 billion in 2012. It is the only Chinese pharmaceutical company whose sales revenue exceeds RMB 100 billion.
With all-out efforts, Sinopharm is promoting the overall construction of five major platforms – the modern integrated distribution and logistics platform, the integrated manufacturing and R&D platform for scientific and technological innovation, the integrated globally operational platform, the health care industry platform and the highly efficient control and integration services platform, to comprehensively advance the joint development of the eleven core business sectors of modern pharmaceutical logistics and distribution; medicine retail; biological products; chemical pharmaceuticals; modern TCM; diagnosis reagents and chemical reagents; scientific instruments and medical equipments; medical scientific research and engineering design; pharmaceutical international trade and overseas industry, pharmaceutical exhibitions and media; health care industry. So far, Sinopharm has formed an immense and complete pharmaceutical and healthcare industrial platform, realized the scale effect and promote a high-speed growth. Since Year 2003 to Year 2011, the annual average growth rate of revenue was 33%, the annual average growth rate of gross profit was 44% and the annual average growth rate of total assets was 35%. Besides the largest pharmaceutical and medical distribution network covering 31 provinces, autonomous regions and municipalities and 30 international standard distribution centers and production bases, Sinopharm also owns the first-class manufacturers for medicines, vaccines, blood products, high-level scientific and technological institutes, massive planting bases for medicinal herbs and most of domestic medicine and health care related professional exhibition brands in China. Since 1980s, Sinopharm has cooperated with renowned multinationals, established dozens of Sino-foreign pharmaceutical joint ventures, e.g. China Otsuka Pharmaceutical Co., Ltd. (COP) and Sino-Swed Pharmaceutical Co., Ltd. (SSPC), jointly conducted international technologic programs with companies from the U.S.A., Japan, France, UK., Germany, Italy and Korea, built up collaborative relationship with the clients from over 100 countries and regions. The broad international cooperation have energetically promoted the operation and management ability of the industry in China.
Adhering to the corporate conception of 'Caring for life, attending to health', Sinopharm and its subsidiaries have always undertaken the responsibility of central reserve, allocation and supply of medicines and health care related products against emergencies disasters and epidemics. Sinopharm staff could be found at the emergency sites of various catastrophic disasters and significant events, e.g. Tangshan Earthquake in 1976, fighting against floods in 1998, prevention and treatment of SARS in 2003, earthquake relief of Wenchuan Earthquake in 2008, control of influenza A H1N1 in 2009, earthquake relief effort of Yushu Earthquake and Zhouqu Mudslide in 2010, Beijing Olympic Games in 2008, National Day parade in 2009, Shanghai Expo 2010 and national measles supplementary immunization in 2010. Sinopharm has been playing an important role in nationwide preventing and curing diseases, securing public health and promoting the development of the industry. Meanwhile, Sinopharm has exported vaccines to India, Thailand, South Korea, Nepal, Sri Lanka, etc., which made great contribution to local public health.
Sinopharm is taking leading positions of 9 medical industry associations, e.g. China Pharmaceutical Industry Association (CPIA), China National Narcotic Drugs Association (CNNDA), China Association of Pharmaceutical Commerce (CAPC), China Pharmaceutical Industry Research and Development Association (Sino-PhIRDA), China Association For Medical Devices Industry (CAMDI), China Association of Traditional Chinese Medicine (CATCM), and China Pharmaceutical Culture Society, etc. as well as the organizer of many pharmaceutical and healthcare exhibitions and conferences, e.g. Phram China.
Sinopharm is aiming to be an international pharmaceutical and healthcare group which covering the whole industrial chain and can give strong impetus to the industry as well as the first Chinese pharmaceutical company of the Global Top 500 Corporations during the period of "the 12th Five-Year-Plan".